期刊
BRITISH JOURNAL OF HAEMATOLOGY
卷 193, 期 4, 页码 798-803出版社
WILEY
DOI: 10.1111/bjh.17414
关键词
myelodysplastic syndromes; mutational analysis; flow cytometry; diagnostic haematology
类别
资金
- MDS-RIGHT - European Union's Horizon 2020 research and innovation program [634789]
- H2020 Societal Challenges Programme [634789] Funding Source: H2020 Societal Challenges Programme
SF3B1 mutations define a distinct subgroup of MDS patients with favorable disease course and high response rates to luspatercept. This study identified immunophenotypic features associated with SF3B1 mutations and showed the impact of mutation type and co-occurrence with chromosome 5q deletion on bone marrow immunophenotype. These findings provide leads for refining prognostication and therapeutic strategies for this specific MDS subgroup.
Splicing factor 3B subunit 1 (SF3B1) mutations define a distinct myelodysplastic syndromes (MDS) patient group with a relatively favourable disease course and high response rates to luspatercept. Few data are available on bone marrow phenotype beyond ring sideroblasts in this subgroup of patients with MDS. In the present study, we identified immunophenotypic erythroid, myelomonocyte and progenitor features associated with SF3B1 mutations. In addition, we illustrate that SF3B1-mutation type is associated with distinct immunophenotypic features, and show the impact of co-occurrence of a SF3B1 mutation and a deletion of chromosome 5q on bone marrow immunophenotype. These genotype-phenotype associations and phenotypic subtypes within SF3B1-MDS provide leads that may further refine prognostication and therapeutic strategies for this particular MDS subgroup.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据